SB-228357

From WikiMD's WELLNESSPEDIA

SB-228357 is a serotonin receptor agonist that was discovered and developed by SmithKline Beecham. It is a potent and selective 5-HT4 receptor agonist, with a pKi of 9.5, and has been used in scientific research to study the function of the 5-HT4 receptor.

History[edit]

SB-228357 was first discovered and developed by the pharmaceutical company SmithKline Beecham. The compound was identified as a potent and selective 5-HT4 receptor agonist, which made it a valuable tool in scientific research to study the function of the 5-HT4 receptor.

Pharmacology[edit]

SB-228357 is a potent and selective 5-HT4 receptor agonist. The 5-HT4 receptor is one of the several different subtypes of the serotonin receptor, which is a group of G protein-coupled receptors that are targeted by a variety of drugs used in the treatment of various disorders, including depression, anxiety, and migraine.

Research[edit]

SB-228357 has been used in scientific research to study the function of the 5-HT4 receptor. The compound's potent and selective agonist activity at the 5-HT4 receptor makes it a valuable tool in this research.

See also[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.


References[edit]


External links[edit]

SB-228357[edit]

  • SB-228357 structure
    SB-228357 structure

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=SB-228357&oldid=6333078"